Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: Preclinical data

Clinical Cancer Research

Volumn 4, Issue 10, 1998, Pages 2529-2535

  Fischel, Jean Louis ^a   Etienne, Marie Christine ^a   Formento, Patricia ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0031755917     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pacagnella, A., Orlando, A., Machiori, C., Zorat, P. L., Cavaniglia, G., Sileni, V. C., Jirillo, A., Tomio, L., Fila, G., and Fede, A. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui tumori della testa e del collo. J. Natl. Cancer Inst., 86: 265-272, 1994.
2. Schneider, M., Etienne, M. C., Milano, G., Thyss, A., Otto, J., Dassonville, O., Mobayen, H., Saudes, L., Guillot, T., and Demard, F. Phase II trial of cisplatin, fluorouracil and pure 1 folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J. Clin. Oncol., 13: 1656-1662, 1995.
3. Kemeny, N., Israel, K., Niedzwiecki, D., Chapman, D., Botet, J., Minsky, B., Vinciguerra, V., Rosenbluth, R., Bosselli, B., and Cochran, C. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin with metastatic colorectal cancer. J. Clin. Oncol., 8: 313-318, 1990.
4. Etienne, M. C., Bernard, S., Fischel, J. L., Formento, P., Gioanni, J., Santini, J., Demard, F., Schneider, M., and Milano, G. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br. J. Cancer, 63: 372-377, 1991.
5. Scanlon, K. J., Newman, E. M., Lu, Y., and Priest, D. G. Biochemical basis of cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc. Natl. Acad. Sci. USA. 83: 8923-8925, 1986.
6. Houghton, J. A., Schmidt, C., and Houghton, P. J. The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthase covalent complex in human colon xenografts. Eur. J. Cancer Clin. Oncol., 18: 347-351, 1982.
7. Shirasaka, T., Shimamoto, Y., Ohshimo, H., Saito, H., and Fukushima, M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent models in vivo. Cancer Chemother. Pharmacol., 32: 167-172, 1993.
8. Omura, K., Misaki, T., Hashimoto, T., Kanehira, E., Watanabe, T., Ishida, F., Watanabe, Y., and Shirasaka, T. Changes in folate concentration in Yoshida sarcoma after administration of leucovorin or cisplatin. Cancer Chemother. Pharmacol., 35: 183-187, 1995.
9. Loerher, P. J., Sr., Turner, S., Kubilis, P., Hui, S., Correa, J., Ansari, R., Stephens, D., Woddburn, R., and Meyer, S. A prospective randomized trial of fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. J. Clin. Oncol., 6: 642-648, 1988.
10. Lévi, F., Dogliotti, L., Perpoint, B., Zidani, R., Giacchetti, S., Chollet, P., Le Rol, A., Llory, J. F., Focan, C., Kunstlinger, F., Adam, R., Vannetzel, J. M., Letourneau, Y., Jasmin, C., Bismuth, P., and Misset, J. L. A multicenter Phase II trial of intensified chronotherapy with oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with previously untreated metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 266, 1997.
11. André T., Bensmaïne, M. A., Louvet, C., Lucas, V., Beerblock, K., Desseigne, F., François, E., Merrouche, Y., Bouché, O., Morvan, F., Carola, E., and De Gramont, A. Addition of oxaliplatin (Eloxatine®) to the same leucovorin (LV) and 5-fluorouracil (FU) bimonthly resimens after progression in patients with metastatic colorectal cancer: preliminary report. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 270, 1997.
12. Mathe, G., Kidani, Y., Triana, K., Brienza, S., Ribaud, P., Goldschmidt, E., Ecstein, E., Despax, R., Musset, M., and Misset, J. L. A Phase I trial of trans-1-diaminocyclohexane oxalato-platinum (L-OHP). Biomed. Pharmacother., 40: 372-376, 1986.
13. Mathe, G., Kidani, Y., Segiguchi, M., Eriguchi, M., Fredj, G., Peytavin, G., Misset, J. L., Brienza, S., De Vassals, F., and Chenu, E. Oxalato-platinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43: 237-250, 1989.
14. De Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., André, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
15. Raymond, E., Buquet-Fagot, C., Djelloul, S., Mester, J., Cvitkovic, E., Allain, P., Louvet, C., and Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs, 8: 876-885, 1997.
16. Kones, R. Folic acid. An update with new recommended daily allowances. South. Med. J., 83: 1454-1458, 1990.
17. Carmichael, J., De Graff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-940, 1987.
18. Chou, T., and Talalay, P. Quantitative analysis of dose-effects relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
19. Tsai, C-M., Hsiao, S-H., Frey, C. M., Chang, K-T., Perng, R-P., Gazdar, A. F., and Kramer, B. S. Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. Cancer Res., 53: 1079-1084, 1993.
20. Scanlon, K. J., Safirstein, R. L., Thies, H., Gross, R. B., Waxman, S., and Guttenplan, J. B. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells. Cancer Res., 43: 4211-4215, 1983.
21. Krebs, H. A., Hems, R., and Tyler, B. The regulation of folate and methionine metabolism. Biochem. J., 158: 351-358, 1976.
22. Gamelin, E., Boisdron-Cell, M., Allain, P., Tureau, A., Brienza, S., Krïkrian, A., Cvitkovic, E., and Larra, F. Pharmacokinetic interference between oxaliplatin (LOHP) and fluorouracil: delayed 5-FU metabolism inhibition by LOHP. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 38: 223, 1997.
23. Milano, G., and Etienne, M. C. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics, 4: 301-306, 1994.
24. Beck, A., Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Renée, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur. J. Cancer, 30: 1517-1522, 1994.
25. Etienne, M. C., Chéradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renée, N., Schneider, M., Thyss, A., Demard, F., and Milano, G. Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J. Clin. Oncol., 13: 1663-1670, 1995.
26. Fischel, J. L., Etienne, M. C., Spector, T., Formento, P., Renée, N., and Milano, G. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin. Cancer Res., 1: 991-996, 1995.
27. Esaki, T., Nakano, S., Tastumoto, T., Kuroki-Migita, M., Mitsugi, K., Nakamura, M., and Niho, Y. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res., 52: 6501-6506, 1992.
28. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 301-308, 1998.
29. Grem, J. L. 5-fluoropyrimidines. In: B. A. Chabner and D. L. Longo (eds). Cancer Chemotherapy and Biotherapy, 2nd ed., pp. 149-211. Philadelphia: Lippincott-Raven, 1996.
30. Rosenberg, J., and Sato, P. Messenger RNA loses the ability to direct in vitro peptide synthesis following incubation with cisplatin. Mol. Pharmacol., 33: 611-616, 1988.